FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Women considering breastfeeding who have inherited BRCA mutations.
Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : How breast cancer patients experience hormone therapy
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Breast cancer patients taking or considering taking hormone therapy
Side effects from hormone therapy are a common reason that many men and women with hormone receptor-positive breast cancer stop treatment early. Some people never start hormone therapy. This study asked patients about their experiences with hormone (or endocrine) therapy. The results suggest that there may be ways to improve the number of patients who stick with therapy. Patients need better ways to manage hormone therapy-related side effects. (1/19/21)
Este artículo está disponible en español.
Read More
Update : FDA approves new imaging drug for detecting spread of prostate cancer
Most relevant for: Men with prostate cancer
On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)
THIS INFORMATION HAS BEEN UPDATED on 5/10/2022: On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Women support delayed removal of ovaries
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.
Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced colorectal cancer and a type of biomarker called MSI-High (MSI-H)
In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with metastatic triple-negative breast cancer
The ASCENT study confirmed an earlier study and showed that the drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)
Read More
Relevance: Medium-Low
Strength of Science: Medium-High
Research Timeline: Animal Studies
Study : The buzz about honeybee venom: Promising early research to treat breast cancer
Relevance: Medium-Low
Strength of Science: Medium-High
Research Timeline: Animal Studies
Most relevant for: People with breast cancer particularly those with HER2-positive or triple-negative breast cancer.
Early research showed that melittin, an ingredient in honeybee venom, may be used to treat HER2-positive and triple-negative breast cancers. This study found that melittin can kill cancer cells. The chemotherapy drug docetaxel more effectively killed breast cancer cells in mice when combined with melittin. It is not known whether melittin would be safe or affect cancer growth in people. While promising, more research must be done before melittin could be used to treat people. (11/10/20)
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Study : Inherited gene mutations found in pancreatic cancer families in Spain
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers
This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Young women with, or at high risk for an inherited BRCA mutation
Inherited mutations in the BRCA1 and BRCA2 genes are linked to a high lifetime risk of breast and other cancers. This study shows that women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. (10/26/20)
Read More
Update : FDA updates reported harmful events linked to breast implants
Most relevant for: People who have or are considering breast implants.
The FDA has updated reported cases of breast implant-associated cancer and breast implant illness. Included in this update is approval of a questionnaire that asks about quality of life and satisfaction with breast implants. (10/20/20). Note: On October 27, 2021 the FDA announced stronger guidance on breast implant safety.
Read More